Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
about
Androgen deprivation therapy in the treatment of advanced prostate cancerInvestigation of reports of sexual dysfunction among male chemical workers manufacturing stilbene derivativesThe association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature reviewThe many ways to make a luminal cell and a prostate cancer cellCardiovascular effects of hormone therapy for prostate cancerHuman steroid biosynthesis for the oncologistChemotherapy and its evolving role in the management of advanced prostate cancerParenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancerParenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Endocrine treatment in prostate cancerAndrogen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.Improving intermittent androgen deprivation therapy: lessons learned from basic and translational researchRegulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Management of complications of prostate cancer treatment.A history of prostate cancer treatmentHormonal treatment for prostate cancer.Diethylstilboestrol for the treatment of prostate cancer: past, present and future.Novel drugs targeting the androgen receptor pathway in prostate cancer.Nilutamide: an antiandrogen for the treatment of prostate cancer.Hot flushes and prostate cancer: pathogenesis and treatment.Herbal supplement PC-Spes for prostate cancer.Androgen deprivation therapy for prostate cancer: new concepts and concerns.Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.Controversies surrounding androgen deprivation for prostate cancer.Assisted reproduction in a patient with Klippel-Trenaunay syndrome: management of thrombophilia and consumptive coagulopathy.Molecular Basis of Steroid Action in the Prostate.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Timing and choice of androgen ablation.Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.Overcoming drug resistance and treating advanced prostate cancerPituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.Prostate cancer. Promising advances that may alter survival rates.Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.Leuprorelin depot injection: patient considerations in the management of prostatic cancerEnzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
P2860
Q24676531-473D7350-EC36-44CE-8211-0DC702C0A67DQ26340993-144B28AF-C82D-4E73-A942-59C4299CE0C0Q26785506-A77B0075-E0D1-499E-B97F-ACD1FF76E2F1Q26797386-47ED75DF-F907-4E17-A94A-18FA3970580FQ26801112-ABDF4ADB-75B0-45B0-A533-1442433AE2E9Q26999384-6519E8FD-3134-451C-9BA9-A4F9639886FBQ27008883-895C5C3F-88B7-435A-BEB1-61CCFF271E3DQ28181459-0B7BDEA6-D99B-442E-82AA-22D193E096D4Q28193725-00199D69-DAB8-40B2-BDEF-0DF2A55613A6Q28277569-61686596-92E7-4773-8E82-C39FD8E22131Q28378298-1346556F-A13D-42A8-BB3E-77A925C247FEQ33736308-4AEE213F-C8E9-46A1-83CD-5A99E76ED6BDQ33922371-8CF466D6-AF48-495E-848E-0317EA11BED3Q33957249-9C3330E1-69FF-4BC5-BC67-5CDABBCF9D26Q33977523-015CCC8E-0948-4A1F-86B5-783CB8022649Q33978360-1AFEB148-A602-4E43-993C-E72016BF8E1AQ34013878-75995ED7-288D-4ECE-B913-5FE79D616FACQ34167174-D4DEE316-8444-4848-8F00-031EAA35B113Q34386403-6B920D56-3237-4251-8E1F-EA45D5947D4BQ34395777-12938BD4-EB62-4068-93F7-15490BEDCF16Q34413500-6E27488A-9FC9-4AA2-97B1-412A0557C586Q34548264-FF80F373-CE0F-46F1-80D9-926FFE349E9AQ34615655-185BC6FF-E7DE-400A-9138-BB3929391C7BQ34617845-9221D139-DA3D-4339-8484-9DE2E01CA966Q34617924-4BD68BDC-5E68-40FF-A3FF-EDA8BD0CE84BQ34617931-AB51FB4D-BF93-4763-BE49-84FECF1C3C69Q34734109-049D17B9-840A-4E98-9378-6FD8C45228E6Q34849222-D73C07FC-373C-4279-BD9F-9E53F518994EQ34861950-558E1838-DBD2-4157-BE74-E1E9AF2A1811Q35024939-CEBEEEA1-83EE-44A7-B536-0EDD7B274887Q35553876-5A9E082C-9FBA-4437-8C2A-02757E9642E5Q35689824-62741F9E-457C-447F-B878-1BD41AD3FCD8Q35847645-84340495-8AEB-4145-8B09-45225038BCD1Q36173646-F16D83BB-426E-4689-8BA4-5DE5883B43DCQ36328812-827D9144-9017-43FD-9390-1D26507A4747Q36432778-931535CC-8A03-48C6-9C44-E76C49D54A33Q36565558-45B7DF25-627F-46AB-8D55-3B4E6FB1B759Q36677464-0EF824C4-1EFC-43B5-AF05-A4AD475F75DFQ36823588-CCD9B469-9ECB-47A4-9EA9-FA98B47F7B69Q37146546-D9FD8F88-E572-4D2E-ADDD-5874F3598DBC
P2860
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
description
1984 nî lūn-bûn
@nan
1984 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@ast
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@en
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@nl
type
label
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@ast
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@en
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@nl
prefLabel
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@ast
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@en
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@nl
P1476
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
@en
P2093
Leuprolide Study Group
P304
P356
10.1056/NEJM198411153112004
P407
P577
1984-11-01T00:00:00Z